Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis


Selskabsmeddelelse

Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis

Genmab A/S

MEDDELELSE
ID:
131651
Type:
Intern viden
Sprog:
Engelsk
Dokument(er):

 
 

TIDSPUNKTER
Offentliggjort:
22.06.2021 | 16:12:31
Registrering:
22.06.2021 | 16:12:31

UDSTEDER
Virksomhed:
Genmab A/S
CVR-nr:
LEI:
529900MTJPDPE4MHJ122

INDBERETTER
Virksomhed:
GlobeNewswire
CVR-nr.:
UK-02775270



Se den originale selskabsmeddelelse hos Finanstilsynet

Find og læs selskabsmeddelelser fra hele Danmark

Scroll til toppen